<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592096</url>
  </required_header>
  <id_info>
    <org_study_id>Zhaoke-2015-01</org_study_id>
    <nct_id>NCT02592096</nct_id>
  </id_info>
  <brief_title>Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol</brief_title>
  <official_title>A Single Dose Phase I Clinical Study of Pazufloxacin Mesilate Ear Drops for the Patients With Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerance, dynamic percolation model of single dose usage&#xD;
      pazufloxacin mesilate ear drops for patients with acute suppurative otitis media or chronic&#xD;
      suppurative otitis media&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerance of pazufloxacin mesilate ear drops</measure>
    <time_frame>24 hours</time_frame>
    <description>Any changes in vital signs; AE/SAE number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK of pazufloxacin mesilate ear drops</measure>
    <time_frame>24 hours</time_frame>
    <description>blood samples will be collected at 0, 0.5, and one of the followed time points 2, 4, 6, 8 hours. AUC will be calculated based on the pazufloxacin mesilate concentration at above timepoints in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of pazufloxacin mesilate ear drops</measure>
    <time_frame>24 hours</time_frame>
    <description>blood samples will be collected at 0, 0.5, and one of the followed time points 2, 4, 6, 8 hours. Cmax will be calculated based on the pazufloxacin mesilate concentration at above timepoints in blood.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>0.1% Pazufloxacin Mesilate Ear Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 drips for ear dropping, 10 minutes for ear bath</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% Pazufloxacin Mesilate Ear Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 drips for ear dropping, 10 minutes for ear bath</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5% Pazufloxacin Mesilate Ear Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 drips for ear dropping, 10 minutes for ear bath</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pazufloxacin mesilate injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3g, 30 minutes for ventricular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% Pazufloxacin Mesilate Ear Drops</intervention_name>
    <arm_group_label>0.1% Pazufloxacin Mesilate Ear Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Pazufloxacin Mesilate Ear Drops</intervention_name>
    <arm_group_label>0.3% Pazufloxacin Mesilate Ear Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Pazufloxacin Mesilate Ear Drops</intervention_name>
    <arm_group_label>0.5% Pazufloxacin Mesilate Ear Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazufloxacin mesilate injection</intervention_name>
    <arm_group_label>Pazufloxacin mesilate injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-65 years old, both gender;&#xD;
&#xD;
          2. Patients with acute or chronic suppurative otitis media, need to be treated partially&#xD;
             by antimicrobial agents;&#xD;
&#xD;
          3. Written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to quinolones antibiotics or severe allergic constitution;&#xD;
&#xD;
          2. Not able to collect otorrhea during the trial;&#xD;
&#xD;
          3. High severity with the need of combined antibiotics treatment;&#xD;
&#xD;
          4. Induced by pathogens, e.g.: fungus, virus (myringitis bullosa);&#xD;
&#xD;
          5. Combined otitis externa (e.g.: ear cellulitis, mumps), intracranial or extracranial&#xD;
             complication (meningitis, cerebral abscess, thrombophlebitis of sigmoid sinus,&#xD;
             Bezold's abscess, ear subperiosteal abscess);&#xD;
&#xD;
          6. Severe disease of cerebral, cardiopulmonary, renal hepatic, circulatory system;&#xD;
&#xD;
          7. Life-threatening disease, e.g.: malignant tumor or AIDS.&#xD;
&#xD;
          8. Renal hepatic dysfunction (ALT, AST â‰¥ 1.5 times of normal maximum level, Cr &gt; normal&#xD;
             maximum level);&#xD;
&#xD;
          9. Confirmed or suspected of alcohol/drug abuse record;&#xD;
&#xD;
         10. Neurological or psychiatric disease leading to inability of cooperation or not willing&#xD;
             to follow the protocol or instruction;&#xD;
&#xD;
         11. Feminine patients who are in gestational, lactation period or having a birth plan in&#xD;
             short-term;&#xD;
&#xD;
         12. Enrolled into other clinical trial in the past 3 months;&#xD;
&#xD;
         13. Not suitable for this trial according to investigator's judgment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiguo Cue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao Municipal Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiguo Xue, MD</last_name>
    <phone>+86-532-82789159</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiguo XUE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety and bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamide Peroxide</mesh_term>
    <mesh_term>Pazufloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

